Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1704562 | 0.98 | TTR (0.46) | TTRALBALDH1A1KDM4EGAA | |
| SCHEMBL30144833 | 0.84 | ALDH1A1 (0.46) | TTRALBALDH1A1KDM4EGAA | |
| SCHEMBL18299704 | 0.84 | ALDH1A1 (0.46) | TTRALBALDH1A1KDM4EGAA | |
| SCHEMBL11277214 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAACA2CA12 | |
| SCHEMBL29443092 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAACA2CA12 | |
| SCHEMBL352155 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAACA2CA12 | |
| SCHEMBL21687453 | 0.80 | TTR (0.52) | TTRALBALDH1A1CA2CA1 | |
| SCHEMBL1743125 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KDM4EGAACA2CA1 | |
| SCHEMBL5503660 | 0.78 | TTR (0.43) | TTRALBALDH1A1KDM4EGAA | |
| SCHEMBL21277388 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865873-A | 2-benzylidene indoline-3-ketone framework compound and synthesis method thereof | 合肥工业大学 | 2024-04-12 | — | — | CN | claimed |
| CN-115894273-B | Method for catalyzing alcohol C (OH) -C bond cleavage and functionalization by iodine-doped nonmetallic catalyst | 常州大学 | 2024-04-09 | — | — | CN | claimed |
| CN-115894273-A | Method for catalyzing alcohol C (OH) -C bond breaking and functionalization by iodine-doped non-metal catalyst | 常州大学 | 2023-04-04 | — | — | CN | claimed |
| CN-111892553-A | Method for synthesizing ammonium acetate mediated benzothiazole compound | 衡阳师范学院 | 2020-11-06 | — | — | CN | claimed |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-115052860-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117865873-A | 2-benzylidene indoline-3-ketone framework compound and synthesis method thereof | 合肥工业大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-115894273-B | Method for catalyzing alcohol C (OH) -C bond cleavage and functionalization by iodine-doped nonmetallic catalyst | 常州大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20230407293-A1 | DNA-ENCODED AND AFFINITY-TAGGED MASKED-WARHEAD COMPOUNDS AND USE THEREOF IN ASSEMBLING LIBRARIES OF SMALL MOLECULES ENABLED FOR LATE-STAGE PURIFICATION AND MULTIPLEXED SCREENING OF COVALENT LIGANDS | MAIANTI JUAN PABLO (US) | 2023-12-21 | — | — | US | disclosed |
| US-6624153-B2 | Derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I:for use as anti-tuberculosis | UNIVERSITY OF SCIENCES IN PHILADELPHIA | 2003-09-23 | — | — | US | disclosed |
| US-20030114531-A1 | Halogenated antituberculosis agents | KOBARFARD FARZAD (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2002092019-A2 | HALOGENATED ANTITUBERCULOSIS AGENTS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | SCIENCES IN PHILADELPHIA, UNIVERSITY OF | 2002-11-21 | — | — | US | disclosed |
| US-6482982-B1 | BACTERICIDES; MYCOBACTERIUM RESISTANCE | UNIVERSITY OF SCIENCES OF PHILADELPHIA | 2002-11-19 | — | — | US | disclosed |
| EP-0971926-A1 | DIHYDROPYRAZINO 1,2-$i(A)-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042710-A1 | DIHYDROPYRAZINO [1,2-A-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 1998-10-01 | — | — | WO | disclosed |
| US-4622217-A | I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230407293-A1 | DNA-ENCODED AND AFFINITY-TAGGED MASKED-WARHEAD COMPOUNDS AND USE THEREOF IN ASSEMBLING LIBRARIES OF SMALL MOLECULES ENABLED FOR LATE-STAGE PURIFICATION AND MULTIPLEXED SCREENING OF COVALENT LIGANDS | DNA2, WRN, DCLRE1A | TTR 4007/4885ALB 3434/4885ALDH1A1 2197/4885 |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | TTR 2866/4885ALB 3739/4885ALDH1A1 4490/4885 |
| US-20030114531-A1 | Halogenated antituberculosis agents | XDH, TST, QSOX1 | TTR 1539/4885ALB 659/4885ALDH1A1 277/4885 |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | XDH, TST, QSOX1 | TTR 1539/4885ALB 659/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.